Volume 6 Issue 4 - International Pharmaceutical Industry

Current Edition

Volume 16, Issue 4

Revisited Cell Cultures and Valuable Methods for Pre-clinical Studies

Clinical Research V6I4

Revisited Cell Cultures and Valuable Methods for Pre-clinical Studies

During the last ten years, the development of transgenic techniques has rendered possible the creation of mutant strains of rodents mimicking human diseases and the ...

17 December 2014 Clinical Research V6I4 | Volume 6 Issue 4

Continue Reading →

Special Report – How to Ensure the Proper Behaviour of Excipients and their Best Possible Use

Drug Discovery, Development & Delivery V6I4

Special Report – How to Ensure the Proper Behaviour of Excipients and their Best Possible Use

As in recent years excipients have proved to be anything but “inert”, ensuring the proper behaviour of excipients in the various phases of the industrial production ...

17 December 2014 Drug Discovery, Development & Delivery V6I4 | Volume 6 Issue 4

Continue Reading →

The Expanding Role of MRI in the Pharmaceutical Industry

Drug Discovery, Development & Delivery V6I4

The Expanding Role of MRI in the Pharmaceutical Industry

With ever-increasing pressure on drug development pipelines and a growing need to demonstrate convincing mechanisms of action as a part of the registration process f...

17 December 2014 Drug Discovery, Development & Delivery V6I4 | Volume 6 Issue 4

Continue Reading →

Developing Healthcare Facilities

Regulatory & Marketplace V6I4

Developing Healthcare Facilities

If you are the operator of a nursing or care home, and you are considering commissioning the building of a new care or nursing home, or extending or refurbishing an ...

17 December 2014 Regulatory & Marketplace V6I4 | Volume 6 Issue 4

Continue Reading →

ISO IDMP – Four Challenges in Preparing Organisations for the July 1, 2016 EMA Deadline

Regulatory & Marketplace V6I4

ISO IDMP – Four Challenges in Preparing Organisations for the July 1, 2016 EMA Deadline

Most pharmaceutical companies face challenges in becoming compliant with the ISO IDMP standards. In this article, Rune Bergendorff, responsible for NNIT’s ISO IDMP s...

17 December 2014 Regulatory & Marketplace V6I4 | Volume 6 Issue 4

Continue Reading →

Regulatory & Marketplace V6I4

How Much Data Should You Include in a Patent Application?

In the life sciences and chemistry fields it is important to be aware that a perceived lack of data in a patent application can have an impact on the eventual scope ...

17 December 2014 Regulatory & Marketplace V6I4 | Volume 6 Issue 4

Continue Reading →

A Hard Pill to Swallow: Meeting the Needs of Modern Consumers

Regulatory & Marketplace V6I4

A Hard Pill to Swallow: Meeting the Needs of Modern Consumers

Confronted with the “patent cliff”, dwindling drug discovery success and a host of other challenges, pharmaceutical companies are being forced to reconsider how they...

17 December 2014 Regulatory & Marketplace V6I4 | Volume 6 Issue 4

Continue Reading →

Cost Savings for Healthcare Estates: Delivered through Improved Waste Management

Regulatory & Marketplace V6I4

Cost Savings for Healthcare Estates: Delivered through Improved Waste Management

You only have to read a newspaper or turn on the news to see how the NHS is struggling to meet the balance between demand for healthcare services and funding. Tony M...

17 December 2014 Regulatory & Marketplace V6I4 | Volume 6 Issue 4

Continue Reading →

“Personal Pill” Regulations: Current Landscape and Future Scenario

Regulatory & Marketplace V6I4

“Personal Pill” Regulations: Current Landscape and Future Scenario

The rapidly-evolving science of pharmacogenetics brought in the amazing concept of “personalisation of medicines” also referred to as the “personal pill”. Balamurali...

17 December 2014 Regulatory & Marketplace V6I4 | Volume 6 Issue 4

Continue Reading →